Dr. Keith A. Friedenberg, M.D.
Gastroenterology (Gastroenterology Physician)
8877 Mentor Ave
Mentor, OH 44060
Who else practices at this address →
Lake County includes primary care (8% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 533
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
OH license 35067316
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
- Lake Health Concord, OH
Medical groups
- Dayton Gastroenterology, LLC (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 533
- Services billed
- 8,814
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 296 | 232 |
| New patient office or other outpatient visit, 30-44 minutes | 183 | 183 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 139 | 138 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 121 | 119 |
| Established patient office or other outpatient visit, 30-39 minutes | 76 | 61 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 52 | 52 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 45 | 45 |
| Dilation of esophagus | 43 | 43 |
| Biopsy of large bowel using a flexible endoscope | 43 | 43 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Mentor, OH | 854 |
| Pantoprazole Sodium Other prescribers in Mentor, OH | 633 |
| Dicyclomine Hcl Other prescribers in Mentor, OH | 359 |
| Famotidine Other prescribers in Mentor, OH | 155 |
| Colestipol Hcl Other prescribers in Mentor, OH | 96 |
| Ondansetron Hcl Other prescribers in Mentor, OH | 79 |
| Budesonide Dr (budesonide) Other prescribers in Mentor, OH | 68 |
| Sutab (sod sulf/pot chloride/mag sulf) | 59 |
| Mesalamine Other prescribers in Mentor, OH | 43 |
| Zenpep (lipase/protease/amylase) Other prescribers in Mentor, OH | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 117 payments worth $23,422 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $21,997 |
|---|---|
| AbbVie Inc. | $287 |
| Aimmune Therapeutics, Inc. | $180 |
| Pfizer Inc. | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | $143 |
| Janssen Biotech, Inc. | $106 |
| Qol Medical, LLC | $84.40 |
| Ipsen Biopharmaceuticals, Inc | $56.67 |
| Compensation for services other than consulting (speaking, faculty) | $20,640 |
|---|---|
| Food and Beverage | $2,735 |
| Travel and Lodging | $46.20 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Cleveland, OH | $36.40 |
| Phathom Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Willoughby, OH | $9.80 |
| Phathom Pharmaceuticals, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 9 companies. The companies reported $574,538 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT06581328 - Study of DONQ52 in Active Celiac Disease
Chugai Pharmaceutical Co., Ltd. - A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06693531 - A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to …
Takeda Pharmaceuticals U.S.A., Inc. - EoE-201
Phathom Pharmaceuticals, Inc. - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc. - TAK-279 CD/UC Ph2 OLE
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.